I'm available for business trips to other cities for projects lasting a month or longer.
Creating a Revolution in Liver Care with AI
Imagine accelerated fatty liver disease detection and treatment strategies — without the traditional drawbacks. We did.
Harnessing the power of AI to revolutionize liver health
Founded in the heart of Silicon Valley (Mountain View, California), Karyon
Bio was born out of a deep commitment to tackling one of the most
pressing health challenges of our time—metabolic dysfunction-associated liver disease (MALD) and its more severe form, metabolic
dysfunction–associated steatohepatitis (MASH).
These conditions, affecting a staggering one-quarter of the global
population, often go undetected until they progress to advanced stages,
leading to severe complications such as cirrhosis, liver failure, and even
liver cancer. When combined with metabolic dysfunctions, the morbidity
associated with MALD/MASH increases exponentially, making early
diagnosis and effective management critical.
Bio was born out of a deep commitment to tackling one of the most
pressing health challenges of our time—metabolic dysfunction-associated liver disease (MALD) and its more severe form, metabolic
dysfunction–associated steatohepatitis (MASH).
These conditions, affecting a staggering one-quarter of the global
population, often go undetected until they progress to advanced stages,
leading to severe complications such as cirrhosis, liver failure, and even
liver cancer. When combined with metabolic dysfunctions, the morbidity
associated with MALD/MASH increases exponentially, making early
diagnosis and effective management critical.
The scientific rationale:
A new frontier in diagnostics
A new frontier in diagnostics
Taking the pain (literally) out of liver disease detection/treatment.
Very approachable
Traditional methods of detecting liver diseases—such as liver
biopsies—are invasive, costly, and carry risks for patients. Moreover, they
often fail to provide comprehensive Read more
Unique solutions demand unique intelligence
By seamlessly integrating multiomics, imaging, clinical, EHR, and other real-world data, our diagnostic tools offer a holistic view of the molecular underpinnings
Read more
Read more
A new type of platform
Our proprietary AI-driven platform leverages advanced machine-learning
algorithms to analyze vast amounts of clinical data, imaging results, and
biomedical literature. There is
Read more
.
Technology
A glimpse under the hood
At Karyon Bio, our solutions stand out for their unprecedented precision
and insight into liver health, offering hope to millions worldwide.
and insight into liver health, offering hope to millions worldwide.
We employ an array of advanced biological methods, including single-cell and spatial transcriptomics, iPSC-derived models, 3D organoids, CRISPR-based functional screens, and microfluidic cell-on-a-chip platforms.
These high-resolution techniques expand our datasets and deepen our understanding of fatty liver disease at cellular and subcellular levels, opening new pathways for breakthrough discoveries.
These high-resolution techniques expand our datasets and deepen our understanding of fatty liver disease at cellular and subcellular levels, opening new pathways for breakthrough discoveries.
Addressing a complex challenge like fatty liver disease requires diverse expertise. Karyon Bio unites specialists in AI, computational biology, genomics, hepatology, radiology, and liver pathology, creating an “in-house synergy.”
This broad collaboration ensures that our research covers every aspect of disease
biology—from molecular foundations to clinical implementation.
This broad collaboration ensures that our research covers every aspect of disease
biology—from molecular foundations to clinical implementation.
Trust in data-driven solutions is vital in healthcare. Our explainable AI approaches illuminate how predictive models arrive at their conclusions, highlighting influential variables and decision pathways.
This transparency fosters confidence among clinicians, researchers, and patients, ensuring our insights are both valid and actionable.
This transparency fosters confidence among clinicians, researchers, and patients, ensuring our insights are both valid and actionable.
Incorporating electronic health records and patient registries offers a longitudinal, real-world perspective on disease progression.
This comprehensive view refines our models, enabling precise identification of at-risk individuals and informing optimal clinical strategies tailored to diverse patient populations.
This comprehensive view refines our models, enabling precise identification of at-risk individuals and informing optimal clinical strategies tailored to diverse patient populations.
We harness sophisticated approaches capable of unifying and analyzing data from multiple modalities—imaging, omics, clinical, and more—within a single framework.
By capturing the relationships and interactions across these diverse datasets, we can uncover hidden disease patterns and correlations, enabling earlier, more accurate detection of fatty liver disease and more precise, patient-specific interventions.
By capturing the relationships and interactions across these diverse datasets, we can uncover hidden disease patterns and correlations, enabling earlier, more accurate detection of fatty liver disease and more precise, patient-specific interventions.
By integrating multi-omics data and AI, we offer a personalized approach to treatment, identifying the most effective therapies based on each patient’s unique molecular profile.
| Our research Karyon Bio is on a mission to transform how fatty liver disease is detected and managed. By uniting multiomics, imaging, clinical, EHR, and other real-world data, we gain a comprehensive view of disease mechanisms. Leveraging our cutting-edge multimodal AI,deep neural networks and ML, we uncover early biomarkers that open the door to precise, non-invasive diagnostics—empowering earlier detection, improved prognosis, and targeted therapies. Through close collaboration with hospitals, biobanks, and other research partners, we harness emerging data-generation approaches—from single-cell and spatial transcriptomics to iPSC-derived models and cell-on-a-chip platforms. These advanced methods enrich our datasets and fuel new discoveries, allowing us to translate biomarker insights into accessible, affordable tests that can fit seamlessly into standard blood panels. This patient-centric strategy reflects our startup’s unwavering commitment to innovate, energize, and redefine the future of liver disease care. |
LIVAID
Karyon Bio's AI-powered medical assistant for researchers
What is LIVAID?
LIVAID is a 'Bio Marker Validator' provides expert information on liver conditions, particularly MASLD and MASH, by integrating advanced language understanding with knowledge graphs and retrieval.
LIVAID is a 'Bio Marker Validator' provides expert information on liver conditions, particularly MASLD and MASH, by integrating advanced language understanding with knowledge graphs and retrieval.
- Ensures AccuracySupports each response with verified academic references and inline citations.
- Deep Insights, Beyond AbstractsLIVAID processes full academic papers for context-aware answers that go beyond standard abstracts.
- Trusted & Up-to-Date InsightsIntegrates a biomedical database and academic literature to provide accurate, real-time responses.
Book your AI-powered demo now!
Select a convenient time to explore how LIVAID works.
To revolutionize liver disease diagnosis and treatment by harnessing the
power of AI and multi-omics technologies—providing early, accurate and
non-invasive solutions that empower healthcare providers and improve
patient outcomes worldwide.
power of AI and multi-omics technologies—providing early, accurate and
non-invasive solutions that empower healthcare providers and improve
patient outcomes worldwide.
Our Mission
To lead the global fight against liver diseases by becoming the foremost
innovator in AI-driven diagnostics, ensuring early detection and personalized care for all. Join us on our journey as we work to bring hope and healing to those affected by liver diseases, harnessing the power of AI to create a healthier world.
innovator in AI-driven diagnostics, ensuring early detection and personalized care for all. Join us on our journey as we work to bring hope and healing to those affected by liver diseases, harnessing the power of AI to create a healthier world.
Our Vision
Our team
The smartest people are working every day to change the future of liver treatment.
- Srinivas ThirunagariFounder & CEORead more
- Dr. Eckart BindewaldChief Scientific OfficerRead more
- Mahati MunikotiCo-Founder, Senior Research Scientist, Bioinformatics & MLRead more
- Kevin P. Erazo CastilloPrincipal Scientist - AI/MLRead more
Our partners
US office
855 Maude Ave, Mountain View, CA 94043, USA
India office
13th Cross Rd, Indiranagar, Bengaluru, Karnataka 560038, India